However, I have to disagree with you about that statement, as it clearly states in the Trial Summary, as pasted here, that it includes both SOC and monotherapy.
"The phase 1 study is an open label, multi-center, non-randomized, dose escalation and
expansion study designed to assess the safety, tolerability, and immunogenicity of
IMU-201(PD1-Vaxx) as monotherapy and in combination Standard of Care (SOC) treatment in
participants with PD-L1 expressing non-small cell lung cancer (NSCLC"
Ann: Imugene First Patient Dosed in PD1-VAXX Clinical Trial, page-67
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |